Resumo
La gliomatosis cerebri es una neoplasia cerebral poco común, que se caracteriza por una infiltración difusa del tejido cerebral, sin formación de masa tumoral. Generalmente, se manifiesta con sintomatología neurológica inespecífica, que depende de la localización de la lesión. Es de difícil diagnóstico, tanto clínico como imagenológico, y puede ser difícil diferenciarla de un amplio número de diagnósticos. En la actualidad no se cuenta con una estrategia terapéutica óptima y el pronóstico de los pacientes con esta enfermedad es muy poco favorable. Se presenta el caso de un paciente masculino de 17 años de edad que desarrolló esta enfermedad, seguido de una revisión de la literatura dispeonible.
Armstrong GT, Phillips PC. Gliomatosis cerebri: 20 years of experience at the Children’s Hospital of Philadelphia. Cancer. 2006;107(7):1597-1606.
Zhao X, Tian Y. Gliomatosis Cerebri. Chin J Clin Oncol. 2008;5:242-250. doi:10.1007/s11805-008-0242-9.
Val Filho DA, Avelar LG. Gliomatosis cerebri with favorable outcome in a child: a case report. J Pediatr (Rio J). 2008;84(5):463-6.
Caroli E, Orlando ER, Ferrante L. Gliomatosis cerebri in children: case report and clinical considerations. Childs Nerv Syst. 2005;21:1000-3. doi:10.1007/s00381-004-1076-2.
Harrison JF, Richard HT. Gliomatosis cerebri: report of 3 cases. J Neurosurg Pediatrics. 2010;6.
Manara R, Marasco R, Citton V, et al. Gliomatosis cerebri a possible clinical and neuroradiologic “stroke mimic”. Neurologist. 2011;17(2)83-5.
Keene DL, Jimenez C. MRI diagnosis of gliomatosis cerebri. Pediatric Neurol. 1999;20(2).
Shin YM, Chang KH, Han MH, et al. Gliomatosis cerebri: comparison of MR and CT features. AJR. Am J Roentgenol. 1993;161(4):859-62.
Fountas KN, Kapsalaki EZ, Gotsis SD. In vivo proton magnetic resonance spectroscopy of brain tumors. Stereotact Funct Neurosurg. 2000;74:83-94.
Bendszus M, Warmuth-Metz M. MR spectroscopy in gliomatosis cerebri. AJNR Am J Neuroradiol. 2000;21:375-80.
Louis DN, Ohgaki H, Wiestler OD. The 2007 WHO classifi cation of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
Walter AH. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer. 1998;82(9):1749-55.
Perkins G, Schomer D, Fuller GN, et al. Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56(4):1137-46.
Levin N, Gomori JM, Siegal T. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology. 2004;63(2):354-6.
Inoue T, Kumabe T, Kanamori M, et al. Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev. 2011;34(2):197-208. doi:10.1007/s10143- 010-0306-1.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.

